[vc_row][vc_column][vc_column_text] In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]
[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
[vc_row][vc_column][vc_column_text] England’s Chief Medical Officer, Dame Sally Davies, recently called for making genomic testing as common as blood tests in order to usher in the era […]
Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the […]
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for […]
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of […]
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously […]
In recent years Next Generation Sequencing instrumentation has become much more accurate, efficient and affordable, enabling researchers to collect, sequence and analyse genomes with increasing ease. […]